ModAstera and Wellgen Medical Join Forces to Innovate AI in Cancer Cytology

ModAstera and Wellgen Medical Collaborate on AI-Driven Cancer Cytology

Introduction

ModAstera Inc., based in Shibuya, Tokyo, has recently announced its strategic partnership with Wellgen Medical CO., LTD, a Taiwan-based firm specializing in tomographic imaging technologies for cytopathology. Together, they will focus on developing AI-driven screening models intended to enhance cancer cytology, particularly in detecting metastatic cancer cells found in body fluids. This collaboration endeavors to leverage Wellgen Medical’s FDA-cleared tomographic imaging technologies and ModAstera's AI development platform to address pressing challenges within oncology diagnostics.

Understanding the Challenges in Pathology

Cytopathology, which involves analyzing cancer cells residing in bodily fluids such as pleural and ascitic fluid, plays an integral role in cancer detection. Despite its importance, the sector is grappling with critical challenges, namely a growing shortage of qualified pathologists and limitations in the sensitivity of current diagnostics.

According to projections, the United States is expected to face a deficit of around 5,000 pathologists by 2030. In Japan, the scenario is no better, with only about 1.4 pathologists available per 100,000 residents, translating to roughly a fifth of the ratios seen in the US.

Furthermore, the sensitivity of current diagnostic methods for detecting metastatic cancer ranges between 32% and 77%, varying with cancer type and methodology. This variance can lead to undetected Stage IV cancer cases, highlighting a crucial gap in timely medical interventions.

The Shortcomings of Traditional AI in Pathology

Most conventional AI solutions in pathology have been built around the analysis of flat histology tissue slices through Whole Slide Imaging (WSI). However, cytopathology presents distinct challenges due to the three-dimensional clustering of cells. Traditional scanners often struggle to visualize overlapping cells, leading to the possibility of critical cancer cells becoming obscured in the process.

The CytoScope platform from Wellgen Medical stands out due to its tomographic imaging capabilities, which enable the visualization of cellular structures in three dimensions, moving beyond the limitations associated with standard scanning technologies. Information typically unattainable by traditional imaging can be effectively analyzed when using this advanced technology.

In merging 3D imaging technology with AI analysis, ModAstera and Wellgen aim to tackle the primary limitations currently confronting digital cytology diagnostics.

Streamlining the Diagnostic Workflow

As part of their partnership, the two companies will work hand-in-hand to develop and validate AI screening models tailored for serous fluid cytology. These models will be integrated into the CytoScope workflow, enhancing the process of cytological evaluation.

The designed AI can pre-screen slides, highlighting potential areas of concern for further assessment by pathologists. This innovation not only aims to decrease the amount of time required for each case but also lays the groundwork for future advancements in telepathology, a field poised to benefit from such technological enhancements.

Future Implications of the Partnership

Through this alliance, ModAstera and Wellgen Medical aim to usher in improved diagnostic accuracy and efficiency, ultimately easing the burdens faced by healthcare professionals. The combined expertise of both firms is primarily directed towards facilitating quicker treatment options for cancer patients while enhancing the workflow efficiency of pathologists.

About ModAstera Inc.

ModAstera is an ambitious startup specializing in medical AI, providing a comprehensive platform that streamlines the processes of data annotation, AI model generation, and cloud deployment. With an aim to drive cost reduction and speed in medical AI developments, their offerings significantly contribute to ongoing innovations in healthcare technology.

Visit ModAstera

About Wellgen Medical CO., LTD

Wellgen Medical is a pioneering medical technology company located in Taiwan, dedicated to improving the field of cytopathology through advanced imaging technologies. With its CytoScope platform, Wellgen Medical seeks to enhance diagnostic accuracy and operational efficiency in the realm of cancer and infectious disease diagnostics.

Visit Wellgen Medical